论文信息 - Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial - 字舞流文

Effect of remdesivir post hospitalization for COVID-19 infection from the randomized SOLIDARITY Finland trial

M. Perola | G. Guyatt | T. Ala-Kokko | V. Jalkanen | M. Myllärniemi | H. Kauma | M. Sinisalo | H. Ansakorpi | J. Rutanen | J. Antonen | K. Sivenius | S. Parkkila | Hanna-Riikka Kreivi | R. Patovirta | Tiina M. Mattila | J. Haukka | K. Tikkinen | I. Kalliala | Erja-Leena Paukkeri | P. Järvinen | T. Kilpeläinen | Iivo Hetemäki | J. Paajanen | P. Salonen | H. Ekroos | I. Kuitunen | J. Mäntylä | S. Lamminmäki | O. Nevalainen | Ville Holmberg | J. Jouppila | T. Partanen | A. Renner | R. Komulainen | Pia Holma | T. Nykänen | Jussi M. J. Mustonen | Susanna Tuominen | Sari Risku | Miro Nyqvist | P. Säilä | N. Pourjamal | Saana Horstia | Sanna Laakkonen | Pauliina Kuutti | Tuomas Rosberg | Taija Rutanen | Joni Savolainen | Tero Jaakko Jutta Heikki Riina Mia Iivo Pia Ville Ville Ala-Kokko Antonen Delany Ekroos Hankkio Hauk | Jutta Delany | Riina Hankkio | Mia Haukipää | Toni Jämsänen | Juuso Järventie | Laura Mäkinen | Gitte Määttä | Joni Niskanen | Emmi Puusti | Emma Reponen | Mari Saalasti | Ville Jalkanen | J. Savolainen

[1] D. Needham,et al. Long COVID: aiming for a consensus , 2022, The Lancet Respiratory Medicine.

[2] M. T. Medina,et al. Remdesivir and three other drugs for hospitalised patients with COVID-19: final results of the WHO Solidarity randomised trial and updated meta-analyses , 2022, The Lancet.

[3] Heidi Ledford. Can drugs reduce the risk of long COVID? What scientists know so far. , 2022, Nature.

[4] P. Ennezat. Outpatient Remdesivir to Prevent Progression to Severe Covid-19. , 2022, The New England journal of medicine.

[5] E. Hadley,et al. Molnupiravir Plus Usual Care Versus Usual Care Alone as Early Treatment for Adults with COVID-19 at Increased Risk of Adverse Outcomes (PANORAMIC): Preliminary Analysis from the United Kingdom Randomised, Controlled Open-Label, Platform Adaptive Trial , 2022, SSRN Electronic Journal.

[6] Janet Diaz,et al. A clinical case definition of post-COVID-19 condition by a Delphi consensus , 2021, The Lancet Infectious Diseases.

[7] G. Poudel,et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection , 2021, JAMA network open.

[8] P. Glasziou,et al. The RECOVERY trial platform: a milestone in the development and execution of treatment evaluation during an epidemic , 2021, Journal of the Royal Society of Medicine.

[9] P. Edison,et al. Long covid—mechanisms, risk factors, and management , 2021, BMJ.

[10] D. Brodie,et al. Post-acute COVID-19 syndrome , 2021, Nature Medicine.

[11] G. Poudel,et al. Short-term and Long-term Rates of Postacute Sequelae of SARS-CoV-2 Infection A Systematic Review , 2021 .

[12] OUP accepted manuscript , 2021, Qjm: An International Journal Of Medicine.

[13] W. Lim,et al. Dexamethasone in Hospitalized Patients with Covid-19 , 2021 .

[14] R. Malekzadeh,et al. Repurposed antiviral drugs for COVID-19; interim WHO SOLIDARITY trial results , 2020, medRxiv.

[15] R. Malekzadeh,et al. COVID-19 clinical trials: learning from exceptions in the research chaos , 2020, Nature Medicine.

[16] E. Mohammadi,et al. Barriers and facilitators related to the implementation of a physiological track and trigger system: A systematic review of the qualitative evidence , 2017, International journal for quality in health care : journal of the International Society for Quality in Health Care.